While this assay reliably detected EGFR amplification, i.e., one of the relevant molecular biomarkers for IDH-wildtype glioblastoma [60], its analytical sensitivity for additional detection of the EGFRvIII variant in EGFR-amplified glioblastomas was lower compared to RT-PCR analysis and immunohistochemistry. The gene discussed is IDH1; the disease is glioblastoma.